Provided by Tiger Trade Technology Pte. Ltd.

Natera

390.79
-4.7700-1.21%
Post-market: 390.790.00000.00%18:04 EDT
Volume:2.44M
Turnover:948.84M
Market Cap:55.97B
PE:-284.65
High:392.96
Open:387.59
Low:380.39
Close:395.56
52wk High:437.41
52wk Low:167.99
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.08
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:30.73
PE(LYR):-255.94

Loading ...

Movement Alert|Natera Rises 5.5% in Regular Trading, Signatera Platform Secures Multiple Clinical Collaborations

Market Focus
·
Jun 04

Natera, CytoDyn collaborate to advance ctDNA-guided development

TIPRANKS
·
Jun 04

Natera partners with CytoDyn on ctDNA analysis for metastatic colorectal cancer study

Reuters
·
Jun 04

Natera President, Clinical Diagnostics Solomon Moshkevich sells USD 652,083.87 in common shares

Reuters
·
Jun 04

Natera director Roelof Botha disposes of 78,000 common shares worth $17.2 million

Reuters
·
Jun 04

Natera appoints oncologists Thomas Lynch, Eric Rubin to board

Reuters
·
Jun 03

Natera Appoints Oncology Leaders DRS. Thomas Lynch and Eric Rubin to Board of Directors

THOMSON REUTERS
·
Jun 03

Natera Coverage Assumed by Wolfe Research at Outperform

Dow Jones
·
Jun 02

Natera assumed with an Outperform at Wolfe Research

TIPRANKS
·
Jun 02

U.S. Supreme Court rejects Natera, CareDx false-advertising dispute

Reuters
·
Jun 02

CareDx denied request to Supreme Court to revive Natera award

TIPRANKS
·
Jun 02

Natera partners with Diakonos Oncology to use Signatera in refractory melanoma trial

Reuters
·
May 29

Natera Announces Collaboration With Diakonos Oncology for Signatera™ in Refractory Melanoma

THOMSON REUTERS
·
May 29

Natera Enrolls First Patients in Study Evaluating MRD-Guided Therapy for Breast Cancer

MT Newswires Live
·
May 28

Natera Clinical Milestones Raise Questions On Growth Versus Valuation Risk

Simply Wall St.
·
May 27

Natera Upgrades Prenatal Test to Improve low Fetal Fraction Accuracy

MT Newswires Live
·
May 26

Natera launches enhanced Panorama NIPT backed by 3,323-patient clinical validation study

Reuters
·
May 26

Natera presents 35 oncology studies at ASCO annual meeting

Reuters
·
May 22

Natera presents ASCO data showing Signatera MRD positivity predicts higher recurrence risk

Reuters
·
May 22

Natera Expands Operations in Austin

MT Newswires Live
·
May 21